广东华商（重庆）律师事务所 关于重庆山外山血液净化技术股份有限公司 2023 年年度股东大会的法律意见书 重庆山外山血液净化技术股份有限公司（以下简称"公司"）2023 年年度 股东大会定于2024 年 5 月 16 日召开，广东华商（重庆）律师事务所（以下简称"本 所"）接受公司的委托，指派孟显慧律师、范央权律师（以下简称"本所律师"） 通过现场参会方式对本次股东大会进行见证，并依据《中华人民共和国公司法》（以 下简称"公司法"）《中华人民共和国证券法》《上市公司股东大会规则》及其他现 行有效的法律、法规及规范性文件规定及《重庆山外山血液净化技术股份有限公司 章程》（以下简称"公司章程"）出具本法律意见书。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料 予以了核查、验证。在进行核查验证过程中，公司已向本所保证，公司提供予本所 之文件中的所有签署、盖章及印章都是真实的，所有作为正本提交给本所的文件都 是真实、准确、完整和有效的，且文件材料为副本或复印件的，其与原件一致和相 符。 在本法律意见书中，本所仅对本次股东大会召集和召开的程序、出席本次股东 大会人员资格和召集人资格及表决程序、表 ...

证券代码：688410 证券简称：山外山 公告编号：2024-030 重庆山外山血液净化技术股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 注：截至本次股东大会股权登记日公司总股本为 215,648,085 股，其中公司 回购专用证券账户中股份数为 1,151,023 股，不享有股东大会表决权；本次会议 公司有表决权股份总数为 214,497,062 股。 （一） 股东大会召开的时间：2024 年 5 月 16 日 （二） 股东大会召开的地点：重庆市两江新区慈济路 1 号 8 楼会议室 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事会召集，董事长高光勇先生主持。会议采用现场投票与 网络投票相结合的表决方式进行表决。本次会议的召集、召开符合《中华人民共 和国公司法》《公司章程》《股东大会议事规则》及《上市公司股东大会规则》等 法律、法规和规范性文件的规定。 （五） 公司董事、监事和董事会秘书的 ...

Group 1: Financial Performance - In 2023, the company achieved a revenue of 528 million CNY from blood purification equipment, with a market share increase that positioned it as the industry leader [2]. - The revenue from blood purification consumables reached 102 million CNY in 2023, reflecting a year-on-year growth of 32.99% [2]. - In Q1 2024, the revenue from blood purification equipment was 118 million CNY, showing a year-on-year growth of 71.59% [2]. Group 2: Market Expansion - The company’s blood purification equipment was sold to over 75 countries, with international sales growing by 98% year-on-year [2]. - In Q1 2024, overseas revenue increased by 80.66%, with significant growth in developing countries such as Thailand, Indonesia, and Colombia [3]. - The company plans to expand its market presence in South America and Africa while also targeting the European market for blood purification devices [3]. Group 3: Product Development - The company has developed a new blood perfusion device that utilizes advanced materials and production techniques, enhancing its clinical safety and reliability [3]. - The full launch of self-produced blood purification consumables is expected to create a synergistic effect, enhancing the company's competitive advantage [2]. - The company is committed to continuous R&D investment to improve product performance and meet the growing demand for blood purification solutions [3]. Group 4: Strategic Response to Market Conditions - The company is adapting to market changes due to policy factors affecting procurement activities, with expectations for a gradual recovery of delayed projects [4]. - A competitive incentive mechanism has been established to encourage innovation among research personnel, including performance assessments and flexible leave policies [4]. - The company is closely monitoring government policies related to equipment updates and consumer exchanges, anticipating potential market growth opportunities [4].

Summary of Conference Call for Company 33000 Company Overview - Company 33000 was established in 2001 and operates in the blood purification equipment and consumables sector, including chain dialysis centers and intelligent management systems, recognized as a national high-tech enterprise [2] - It is a leading enterprise in the blood purification industry in China and the only company listed on the Sci-Tech Innovation Board in this sector [2] - Products are sold to thousands of medical institutions domestically and internationally, with exports to 75 countries and regions [2] Core Business Insights - The company focuses on continuous innovation and R&D in blood purification technology, with significant investments in developing new products and enhancing existing ones [3][4] - As of the end of the reporting period, the company has established seven chain dialysis centers, providing services to kidney disease patients [4] Financial Performance - In 2023, the company reported a revenue of 690 million RMB, an increase of 80.6% year-on-year [10] - Domestic revenue was 590 million RMB, up 78.95%, while international revenue approached 100 million RMB, growing by 91.65% [10] - Revenue from blood purification equipment reached 450 million RMB, a 179.64% increase, accounting for 76.49% of total revenue [11] - Continuous blood purification equipment (CRRT) revenue was 250 million RMB, growing by 300% [11] - The gross margin for blood purification equipment was 61.21%, up 4.69% year-on-year [12] R&D and Innovation - R&D investment for 2023 was 38.03 million RMB, a 42.62% increase, representing 5.51% of total revenue [6][15] - The company employs 142 R&D personnel, a 47.92% increase, emphasizing the importance of technological innovation [7][15] - The company has received multiple patents and awards, enhancing its competitive edge in the market [9][8] Future Development Plans - The company plans to invest 2 billion RMB in a blood purification industrial park, which will significantly increase production capacity and optimize product structure [18] - Short-term goals include strengthening the entire blood purification industry chain and increasing market share in China [19] - Mid-term goals involve obtaining FDA certification and establishing a global R&D center to enhance international market presence [20] - Long-term goals focus on mergers and acquisitions to lead the blood purification industry globally [20] Profit Distribution - The company proposed a profit distribution plan, offering a cash dividend of 2 RMB for every 10 shares and a capital reserve increase of 4.9 shares for every 10 shares [21]

Investment Rating - The report suggests maintaining attention on the company due to its continuous growth and market potential [1][4]. Core Insights - The company achieved a significant revenue increase of 80.65% in 2023, reaching 690 million yuan, with a net profit of 194.5 million yuan, up 228.34% [1]. - The first quarter of 2024 saw a revenue decline of 16.03% to 160 million yuan, with a net profit drop of 54.10% to 34 million yuan [1]. - The company has a strong market presence in blood purification equipment, with a 22.92% market share in CRRT, ranking first in sales among domestic brands [1]. - The company is expanding its international market presence, achieving sales in 75 countries, with overseas revenue growing by 91.65% in 2023 [1]. Summary by Sections Financial Performance - In 2023, the company reported total revenue of 690.11 million yuan, with a year-on-year growth rate of 80.65% [6]. - The net profit attributable to the parent company was 194.50 million yuan, reflecting a growth rate of 228.34% [6]. - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares, amounting to 70 million yuan, which is 36.94% of the net profit [1]. Market Position - The company has rapidly increased its market share in blood purification devices, with a revenue of 528 million yuan in 2023, up 118.48% year-on-year [21]. - The blood purification consumables segment generated 102 million yuan in revenue, a 32.99% increase from the previous year [1]. Research and Development - The company invested 38.03 million yuan in R&D in 2023, a 42.6% increase, resulting in the acquisition of multiple patents and medical device registrations [1]. - The gross margin improved to 54.07%, driven by the higher proportion of high-margin blood purification equipment sales [1]. Future Projections - The company forecasts profits of 250 million yuan, 350 million yuan, and 460 million yuan for 2024, 2025, and 2026, respectively, with corresponding PE ratios of 21, 15, and 11 [1][4]. - The blood purification equipment segment is expected to grow at rates of 3%, 21%, and 3% from 2024 to 2026, while consumables are projected to grow significantly [20].

重庆山外山血液净化技术股份有限公司 2023 年年度股东大会会议资料 证券代码：688410 证券简称：山外山 重庆山外山血液净化技术股份有限公司 2023 年年度股东大会 会议资料 2024 年 5 月 16 日 重庆山外山血液净化技术股份有限公司 2023 年年度股东大会会议资料 目录 | 2023 | 年年度股东大会会议须知 3 | | --- | --- | | 2023 | 年年度股东大会会议议程 5 | | 2023 | 年年度股东大会会议议案 7 | | 议案一：关于 2023 | 年年度报告及其摘要的议案 7 | | 议案二：关于 2023 | 年度董事会工作报告的议案 8 | | 议案三：关于 2023 | 年度监事会工作报告的议案 9 | | 议案四：关于 2023 | 年度独立董事述职报告的议案 10 | | 议案五：关于 2023 | 年度财务决算报告的议案 11 | | 议案六：关于确认 2023 | 年度董事薪酬金额及 2024 年度董事薪酬方案的议案.12 | | 议案七：关于确认 2023 | 年度监事薪酬金额及 2024 年度监事薪酬方案的议案.13 | | 议案八：关于 2 ...

证券代码：688410 证券简称：山外山 公告编号：2024-029 重庆山外山血液净化技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 截至 2024 年 4 月 30 日，公司已累计回购公司股份 1,151,023 股，占公司总 股本 215,648,085 股的比例为 0.53%，回购成交的最高价为 27.30 元/股，最低价 为 25.17 元/股，支付的资金总额为人民币 30,098,550.45 元（不含印花税、交易 佣金等交易费用）。 上述回购股份符合法律法规的规定及既定的回购股份方案。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出回 购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务，敬请 广大投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/29 | | --- | --- | | 回购方 ...

西部证券股份有限公司 关于重庆山外山血液净化技术股份有限公司 | | 发布的业务规则及其他规范性文件，并切实履 | 律、法规、部门规章和上海证券交 | | --- | --- | --- | | | 行其所做出的各项承诺 | 易所发布的业务规则及其他规范 | | | | 性文件，切实履行其所做出的各项 | | | | 承诺 | | 7 | 督导上市公司建立健全并有效执行公司治理 | 保荐人督促山外山依照相关规定 | | | 制度，包括但不限于股东大会、董事会、监事 | 健全完善公司治理制度，并严格执 | | | 会议事规则以及董事、监事和高级管理人员的 | 行公司治理制度，督导董事、监事、 | | | 行为规范等 | 高级管理人员遵守行为规范 | | 8 | 督导上市公司建立健全并有效执行内控制度， | 保荐人对山外山的内控制度的设 | | | 包括但不限于财务管理制度、会计核算制度和 | 计、实施和有效性进行了核查，山 | | | 内部审计制度，以及募集资金使用、关联交易、 | 外山的内控制度符合相关法规要 | | | 对外担保、对外投资、衍生品交易、对子公司 | 求并得到了有效执行，能够保证公 | | | ...

西部证券股份有限公司 关于重庆山外山血液净化技术股份有限公司 2023 年度持续督导工作现场检查报告 西部证券股份有限公司（以下简称"保荐人"）作为正在履行重庆山外山血 液净化技术股份有限公司（以下简称"山外山"、"公司"）持续督导工作的保荐 人，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公司自律监 管指引第 11 号——持续督导（2023 年 8 月修订）》等有关法律、法规的规定，对 公司 2023 年度（以下简称"本持续督导期间"）的规范运作情况进行了现场检查， 现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 西部证券股份有限公司 （二）保荐代表人 邹扬、热孜叶·吾浦尔 （三）现场检查时间 （六）现场检查手段 1 1、查看公司主要生产经营场所； 2、对公司高管等人员进行访谈； 3、查阅公司持续督导期间召开的历次股东大会、董事会、监事会会议文件； 2024 年 4 月 22 日至 2023 年 4 月 26 日 （四）现场检查人员 热孜叶·吾浦尔、朱威 （五）现场检查内容 公司治理及内部控制、信息披露、独立性、与关联方的资金往来、募集资金 使用情况、关联交易、对外 ...

重庆山外山血液净化技术股份有限公司 2024 年度"提质增效重回报"行动方案 重庆山外山血液净化技术股份有限公司（以下简称"公司"）认为提高上市 公司质量，增强投资者回报，提升投资者的获得感，是上市公司发展的应有之义， 是上市公司对投资者的应尽之责。为践行"以投资者为本"的上市公司发展理念， 维护公司全体股东利益，基于对公司未来发展前景的信心、对公司价值的认可和 切实履行社会责任，公司特制定 2024 年度"提质增效重回报"行动方案，以进 一步提升公司经营效率，强化市场竞争力，保障投资者权益，稳定股价，树立良 好的资本市场形象。 公司 2024 年度"提质增效重回报"行动方案主要措施如下： 一、聚焦经营主业，提升核心竞争力 公司自成立以来，坚持以技术创新驱动为发展战略，以市场需求为导向，长 期专注聚焦血液净化行业，积极响应国家医疗器械高质量发展的产业政策，不断 拓展产品线，形成了血液透析机、连续性血液净化设备、血液灌流机等全系列血 液净化设备，透析器、灌流器、管路和透析液/粉等多种类血液净化耗材和血透 中心智能管理系统软件，以及连锁血透中心医疗服务等血液净化全产业链布局。 在 2024 年，公司将持续发挥血液 ...